Clinical Impact of New HIV Data From EACS 2021*

Download All
October 27-30, 2021; London, United Kingdom
Get the latest data from EACS 2021 on practical management strategies and the latest data for HIV. Explore key studies from this important international conference in the on-demand webinars, Capsule Summaries, and ClinicalThought expert commentaries. Share the downloadable slidesets with colleagues.


Capsule Summary Slidesets

In combined analysis of open-label extension, maintenance of virologic suppression was demonstrated through 192 weeks.

Released: November 3, 2021

Across phase III/IIIb trials through Week 48, LA CAB + RPV maintained high rates of virologic suppression across dosing strategies and BMI categories; no participant with BMI ≥30 kg/m2 as only baseline risk factor met CVF criterion.

Released: November 5, 2021

Renal safety of daily TDF/FTC for PrEP acceptable, with few serious renal adverse events and none leading to permanent treatment discontinuation.

Released: November 1, 2021

Maraviroc ± metformin, in addition to ART, was safe with acceptable tolerability but did not reduce liver fat percentage vs no adjunctive treatment.

Released: November 3, 2021

Through 26 weeks, viral rebound on lenacapavir plus optimized background was associated with a lack of additional active ARVs resulting in functional LEN monotherapy.

Released: November 5, 2021

In the phase IIb trial, continued high rates of efficacy were seen in the combined ISL plus DOR arm at 144 Weeks; no participants in this arm met criteria for resistance testing.

Released: November 3, 2021

In open-label study, 2-drug regimen was found to be safe and effective at maintaining virologic suppression in patients with multiple previous virologic failures and historic or current M184V/I.

Released: November 2, 2021

Change in serum IL-6 levels from baseline to Week 96 were similar between patients with virologic suppression who switched to DTG/3TC and those who continued TAF-based ART.

Released: November 4, 2021

Participants found LA CAB + RPV to be an acceptable, appropriate, and feasible treatment option for maintenance of HIV virologic suppression from Months 1 to 4.

Released: November 2, 2021

In this small test-and-treat study, regimen was more than 80% effective at suppressing HIV-1 RNA at Week 24 with no treatment-emergent resistance seen in patients who did not achieve viral suppression; very low incidence of grade 3/4 or serious adverse events was seen.

Released: November 2, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings